GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » EV-to-EBITDA

Cargo Therapeutics (Cargo Therapeutics) EV-to-EBITDA : -3.33 (As of May. 31, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cargo Therapeutics's enterprise value is $387.44 Mil. Cargo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-116.35 Mil. Therefore, Cargo Therapeutics's EV-to-EBITDA for today is -3.33.

The historical rank and industry rank for Cargo Therapeutics's EV-to-EBITDA or its related term are showing as below:

CRGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.92   Med: 0   Max: 0
Current: -3.33

CRGX's EV-to-EBITDA is ranked worse than
100% of 453 companies
in the Biotechnology industry
Industry Median: 9.26 vs CRGX: -3.33

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-31), Cargo Therapeutics's stock price is $19.00. Cargo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.027. Therefore, Cargo Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Cargo Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Cargo Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics EV-to-EBITDA Chart

Cargo Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -6.21

Cargo Therapeutics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only - - - -6.21 -4.56

Competitive Comparison of Cargo Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Cargo Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cargo Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's EV-to-EBITDA falls into.



Cargo Therapeutics EV-to-EBITDA Calculation

Cargo Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=387.441/-116.348
=-3.33

Cargo Therapeutics's current Enterprise Value is $387.44 Mil.
Cargo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-116.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cargo Therapeutics  (NAS:CRGX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cargo Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=19.00/-3.027
=At Loss

Cargo Therapeutics's share price for today is $19.00.
Cargo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.027.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Cargo Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cargo Therapeutics (Cargo Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing strategy are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. Their lead program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics (Cargo Therapeutics) Headlines